INT7364

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1986
Last Reported 2009
Negated 8
Speculated 2
Reported most in Abstract
Documents 49
Total Number 52
Disease Relevance 8.05
Pain Relevance 19.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Ghrh) extracellular region (Ghrh)
Anatomy Link Frequency
pituitary 7
plasma 5
nucleus 2
neuronal 2
somatotrope 1
Ghrh (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Somatostatin 112 100.00 Very High Very High Very High
Clonidine 91 100.00 Very High Very High Very High
antagonist 62 100.00 Very High Very High Very High
agonist 35 100.00 Very High Very High Very High
Enkephalin 27 100.00 Very High Very High Very High
Neuropeptide 23 100.00 Very High Very High Very High
substance P 21 100.00 Very High Very High Very High
Neurotransmitter 12 100.00 Very High Very High Very High
Dynorphin 5 100.00 Very High Very High Very High
Arthritis 9 99.98 Very High Very High Very High
Disease Link Frequency Relevance Heat
Arthritis 10 99.98 Very High Very High Very High
Aging 77 99.62 Very High Very High Very High
Obesity 29 99.26 Very High Very High Very High
Prostate Cancer 3 98.84 Very High Very High Very High
Overdose 2 98.72 Very High Very High Very High
Frailty 21 98.36 Very High Very High Very High
Cushing's Syndrome /

Hypercortisolism

5 98.36 Very High Very High Very High
Hypoglycemia 7 97.88 Very High Very High Very High
Pain 6 97.46 Very High Very High Very High
Depression 4 96.72 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore AIA affects significantly neither hypothalamic somatostatin and GHRH mRNA levels nor pituitary GH content.
Neg (neither) Regulation (affects) of GHRH in pituitary associated with somatostatin and arthritis
1) Confidence 0.58 Published 1996 Journal Neuroendocrinology Section Abstract Doc Link 8839359 Disease Relevance 0.88 Pain Relevance 0.66
Rather, age-related changes involving the function of specific hypothalamic peptides for GH regulation, GH-releasing hormone (GHRH) and somatostatin (SS), appear to be the fundamental factors.
Regulation (regulation) of GH-releasing hormone associated with somatostatin
2) Confidence 0.50 Published 2002 Journal Neurobiol. Aging Section Abstract Doc Link 12392795 Disease Relevance 0.26 Pain Relevance 0.27
In the presence of propranolol (10(-5) M), a beta-adrenergic blocking agent, clonidine (10(-5) and 10(-4) M) stimulated GRF release more prominently in a dose-related manner, whereas propranolol (10(-5) and 10(-4) M) by itself did not affect the spontaneous GRF release.
Neg (not) Regulation (affect) of GRF associated with clonidine
3) Confidence 0.45 Published 1986 Journal Endocrinology Section Abstract Doc Link 2873027 Disease Relevance 0 Pain Relevance 0.28
Growth Hormone-Releasing Hormone (GHRH) is the main factor, which regulates GH secretion and somatotrope proliferation.
Regulation (regulates) of Growth Hormone-Releasing Hormone in somatotrope
4) Confidence 0.45 Published 2005 Journal Endokrynol Pol Section Abstract Doc Link 16821213 Disease Relevance 0.40 Pain Relevance 0
Effect of acute and chronic administration of clonidine on hypothalamic content of growth hormone-releasing hormone and somatostatin in the rat.
Regulation (Effect) of growth hormone-releasing hormone associated with somatostatin and clonidine
5) Confidence 0.45 Published 1991 Journal J. Endocrinol. Section Title Doc Link 1686052 Disease Relevance 0 Pain Relevance 0.50
Opiates activate GRF neurons regulating GH release.
Regulation (regulating) of GRF in neurons associated with opiate
6) Confidence 0.45 Published 1997 Journal Peptides Section Abstract Doc Link 9149291 Disease Relevance 0 Pain Relevance 0.48
The effects of the alpha-2 adrenoceptor agonist clonidine (CLO) on the growth hormone (GH) regulatory neuronal systems, growth hormone-releasing hormone (GHRH) and somatostatin (SS), were studied in adult male rats given a single or a short-term administration (1, 3 and 6 days) of the drug.
Regulation (effects) of GHRH in neuronal associated with somatostatin, agonist and clonidine
7) Confidence 0.45 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8632352 Disease Relevance 0 Pain Relevance 0.62
This result suggests that GHRH is not involved in the GH rebound following somatostatin withdrawal in food-deprived rats.
Neg (not) Regulation (involved) of GHRH associated with somatostatin and withdrawal
8) Confidence 0.45 Published 1992 Journal Life Sci. Section Abstract Doc Link 1347904 Disease Relevance 0.13 Pain Relevance 0.34
The growth hormone (GH) responses to GH-releasing hormone (GRF, 3 micrograms/kg i.v.) or clonidine (CLO, 100 micrograms/kg, i.v.), either given alone or in combination, were tested in male rats in which norepinephrine synthesis had been previously blocked with the dopamine-beta-hydroxylase inhibitor diethyldithio-carbamate (DDTC, 400 mg/kg i.p.).
Regulation (responses) of GRF associated with dopamine and clonidine
9) Confidence 0.44 Published 1993 Journal Neuroendocrinology Section Abstract Doc Link 7901787 Disease Relevance 0 Pain Relevance 0.41
Despite these profound biochemical alterations, the GH responsiveness to GHRH and FK 33-824 administration was preserved, while the latter drug induced a lower PRL rise in GH-treated than in control rats.
Regulation (responsiveness) of GHRH
10) Confidence 0.42 Published 1987 Journal J. Endocrinol. Invest. Section Abstract Doc Link 2957419 Disease Relevance 0 Pain Relevance 0.39
The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-dopa, and clonidine-induced GH secretion in normal subjects.
Regulation (effects) of GHRH associated with antagonist and clonidine
11) Confidence 0.39 Published 1996 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 8626863 Disease Relevance 0 Pain Relevance 0.49
One hundred micrograms of GHRH-Ant (iv for 75 min) did not inhibit plasma GH responses to bolus injection of 100 micrograms and 10 micrograms GHRH or simultaneous infusion of 5 micrograms GHRH (iv for 75 min).
Regulation (responses) of GHRH in plasma
12) Confidence 0.39 Published 1996 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 8626863 Disease Relevance 0 Pain Relevance 0.44
One hundred micrograms of GHRH-Ant (iv for 75 min) did not inhibit plasma GH responses to bolus injection of 100 micrograms and 10 micrograms GHRH or simultaneous infusion of 5 micrograms GHRH (iv for 75 min).
Regulation (responses) of GHRH in plasma
13) Confidence 0.39 Published 1996 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 8626863 Disease Relevance 0 Pain Relevance 0.45
The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-dopa, and clonidine-induced GH secretion in normal subjects.
Regulation (effects) of growth hormone-releasing hormone associated with antagonist and clonidine
14) Confidence 0.39 Published 1996 Journal J. Clin. Endocrinol. Metab. Section Title Doc Link 8626863 Disease Relevance 0 Pain Relevance 0.49
The effects of the alpha-2 adrenoceptor agonist clonidine (CLO) on the growth hormone (GH) regulatory neuronal systems, growth hormone-releasing hormone (GHRH) and somatostatin (SS), were studied in adult male rats given a single or a short-term administration (1, 3 and 6 days) of the drug.
Regulation (effects) of hormone-releasing hormone in neuronal associated with somatostatin, agonist and clonidine
15) Confidence 0.39 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8632352 Disease Relevance 0 Pain Relevance 0.62
Moreover, we describe the effect of these SS antagonists on the GH response to GHRH after short-term high-dose dexamethasone (DEX) treatment in young male rats.
Regulation (response) of GHRH associated with antagonist, somatostatin and dexamethasone
16) Confidence 0.38 Published 2002 Journal Endocrinology Section Abstract Doc Link 11897676 Disease Relevance 0 Pain Relevance 0.65
Treatment of ewes with MB, however, limited the ability of clonidine-induced mechanisms to increase concentrations of GH, but did not affect pituitary responsiveness to GHRH (P < .01).
Neg (not) Regulation (affect) of GHRH in pituitary associated with clonidine
17) Confidence 0.38 Published 1997 Journal J. Anim. Sci. Section Abstract Doc Link 9159285 Disease Relevance 0 Pain Relevance 0.34
On different day sessions, naloxone, GHRH, or saline were administered as controls.
Regulation (controls) of GHRH associated with narcan
18) Confidence 0.37 Published 1987 Journal Metab. Clin. Exp. Section Abstract Doc Link 3100909 Disease Relevance 0 Pain Relevance 0.57
This study demonstrates that, in the obese Zucker rat, an alteration of the GH response to GRF is evident by the 8th week of life.
Regulation (response) of GRF associated with obesity
19) Confidence 0.36 Published 1990 Journal Regul. Pept. Section Abstract Doc Link 2139233 Disease Relevance 0.76 Pain Relevance 0.04
A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor.
Regulation (using) of GHRH associated with antagonist
20) Confidence 0.34 Published 1998 Journal Eur. J. Endocrinol. Section Abstract Doc Link 9849822 Disease Relevance 0 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox